Article Text

other Versions

PDF
Current therapy for bronchiolitis
  1. Prasad Nagakumar,
  2. Iolo Doull
  1. Department of Paediatric Respiratory Medicine/Paediatric Cystic Fibrosis Centre, Children's Hospital for Wales, Cardiff, UK
  1. Correspondence to Iolo Doull, Department of Paediatric Respiratory Medicine/Paediatric Cystic Fibrosis Centre, Children's Hospital for Wales, Cardiff CF14 4XW, UK

Abstract

Bronchiolitis is a common, self-limiting, seasonal viral respiratory tract infection in infancy accounting for the majority of hospital admissions in this age group. Supportive care is the mainstay of treatment, concentrating on fluid replacement, gentle suctioning of nasal secretions, prone position (if in hospital), oxygen therapy and respiratory support if necessary. There is a long history of pharmacological agents offering no benefit in acute bronchiolitis. More recently, nebulised epinephrine has been demonstrated to offer short term benefits, while two stratagems have shown promise in decreasing risk of hospitalisation and length of hospital stay. The combination of oral dexamethasone with nebulised epinephrine potentially decreases the need for hospitalisation, while nebulised 3% hypertonic saline mixed with a bronchodilator decreases the length of hospitalisation. Although both stratagems appear safe and well tolerated, their role in clinical practice remains unclear.

Statistics from Altmetric.com

Footnotes

  • Competing interests None.

  • Provenance and peer review Commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.